Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2a, Dose-Escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intraperitoneal Administration of DTA-H19 in Subjects With Advanced Stage Ovarian Cancer.

Trial Profile

Phase 1/2a, Dose-Escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intraperitoneal Administration of DTA-H19 in Subjects With Advanced Stage Ovarian Cancer.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inodiftagene-vixteplasmid (Primary)
  • Indications Carcinoma; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Sponsors Anchiano Therapeutics; BioCancell Therapeutics
  • Most Recent Events

    • 01 Oct 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Mar 2012 Results from this trial show that primary endpoint has been met and signs of efficacy observed at 240 mg dose. BioCancell is acting to expand the trial at highest dosage group.
    • 06 Feb 2012 Additional lead trial investigator (Ronnie Shapira-Frommer) identified as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top